Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that ...

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic ...